Swedish company Orexo has purchased the exclusive US rights to vorvida, a digital therapy to treat alcohol use disorder (AUD), from GAIA, for an undisclosed sum.

In August, Orexo signed an agreement with GAIA to secure exclusive secure global commercial rights to OXD01, a digital therapy being developed to treat OUD.

Under the deal, Orexo will take responsibility for the regulatory approval and commercialisation of vorvida digital therapy in the US.

The deal allows GAIA to secure an upfront payment, milestone payments and royalties.

Both firms will also negotiate with the FDA regarding the regulatory pathway of digital therapy to help determine the timing of the therapy’s launch in the US and the need for additional investments.

GAIA CEO and founder Dr Mario Weiss said: “Working with the Orexo team on the first agreement showed us their dedication and vision of the potential for digital therapeutics in the field of addiction.”

GAIA has leveraged its broca artificial intelligence (AI)-expert system to develop the Vorvida, a fully automated digital therapy that scientifically demonstrated a reduction in problematic drinking patterns in adults with AUD.

In a randomised controlled study that saw the participation of 608 adults suffering from a drinking problem, the researchers found that participants in the intervention group with vorvida significantly reduced their daily alcohol consumption over three and six months.

Furthermore, vorvida users reported fewer days of binge drinking and drunkenness compared to the control group and expressed high acceptance and utility rates of the therapy.

GAIA has already introduced vorvida digital therapy in Germany and Switzerland this year.

Orexo CEO and president Nikolaj Sørensen said: “We are delighted to extend our partnership with GAIA and proud that Orexo may also be able to address alcohol dependency, another major addiction crisis.

“We see a significant unmet need in the treatment of alcohol use disorder and are impressed by the clinical effects that vorvida can deliver for patients.”